Improved survival of patients with myelofibrosis in the last decade: Single-center experience
Last Updated: Wednesday, February 9, 2022
Among 844 patients newly diagnosed with myelofibrosis, median survival in the past decade improved from 48 months to 63 months (P < .001; HR, 0.78 [95% CI, 0.64-0.95]), according to data from a single-center, retrospective study of patients treated from 2000-2010 (n = 373) and 2011-2020 (n = 471). Patients exposed to JAK inhibitor ruxolitinib (n = 532) also had a superior median overall survival of 84 months (95% CI, 70-94 months).
Advertisement
News & Literature Highlights
